THZ531

Target: This ligand targets cyclin-dependent kinases CDK12 and CDK13 in biochemical or cellular target-engagement studies.

Mechanism of Action: Used as the target-protein recognition element, this ligand provides the binding interface for cyclin-dependent kinases CDK12 and CDK13. In PROTAC design, a derivatizable position on the ligand can be connected through an optimized linker to an E3 ligase ligand, such as a CRBN, VHL, or IAP recruiter, while preserving productive target engagement. The resulting bifunctional molecule brings cyclin-dependent kinases CDK12 into proximity with the recruited E3 ligase, enabling ternary-complex formation. If the complex has favorable geometry and residence time, target lysine ubiquitination is promoted, leading to proteasome-dependent degradation in experimental systems.

• PROTAC-Based Kinase Degradation: THZ531 can be used as a ligand to build PROTACs that recruit a chosen E3 ligase and drive selective degradation of its kinase target. This enables mechanistic studies of kinase turnover, pathway rewiring, and dependency shifts by comparing degradation potency with occupancy and phosphorylation readouts.

• E3 Ligase Recruitment Optimization: The ligand can serve as a warhead in PROTAC design to systematically tune linker length, attachment sites, and E3 ligase selection. Such optimization helps maximize ternary complex formation and ubiquitination efficiency, allowing researchers to map structure–degradation relationships and identify conditions that produce sustained target loss.

• Proteome-Wide Mechanism Mapping: THZ531-based PROTACs can be applied in targeted proteomics workflows to quantify degradation breadth and kinetics across signaling networks. By monitoring changes in downstream substrates and compensatory proteins, investigators can distinguish degradation-driven effects from mere inhibition and refine causal models of kinase-driven phenotypes.

• Resistance and Switch Studies: In PROTAC research, THZ531-derived constructs can be used to test whether targeted degradation overcomes resistance mechanisms associated with kinase inhibitors. Comparing phenotypic outcomes under degradation versus inhibition can reveal whether altered signaling, target mutations, or pathway bypass reduces sensitivity to catalytic blockade.

Structure: The structure of THZ531 is characterized by primary or secondary amine/basic nitrogen centers; amide/urea/sulfonamide hydrogen-bonding motifs; halogenated aryl/heteroaryl ring system; heteroaromatic protein-recognition scaffold. These features provide defined hydrogen-bonding, hydrophobic, and steric elements that can support affinity retention while enabling analogue-based linker-vector selection.

Reactivity: The amine/basic nitrogen-containing motif can be evaluated for acylation, sulfonylation, alkylation, or carbamate/urea linker installation when that vector is solvent exposed. For PROTAC construction, the POI ligand can be paired with CRBN ligands such as thalidomide, pomalidomide, or lenalidomide analogues, VHL ligands such as VH032 derivatives, or less common IAP/MDM2/cIAP-recruiting ligands, with alkyl, PEG, piperazine, triazole, or amide linkers screened for ternary-complex formation. In practice, incorporation into PROTACs should begin from derivatives that preserve the reported binding pharmacophore, followed by systematic variation of linker length, polarity, rigidity, and exit-vector geometry to optimize target engagement, E3 recruitment, and cellular degradation readouts.